Death receptors and melanoma resistance to apoptosis

被引:184
作者
Ivanov, VN [1 ]
Bhoumik, A [1 ]
Ronai, Z [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA
关键词
melanoma; apoptosis; death receptors; Fas; TNFR-1; TRAIL;
D O I
10.1038/sj.onc.1206456
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Impaired ability to undergo programmed cell death in response to a wide range of external stimuli acquires melanomas a selective advantage for progression and metastasis as well as their notorious resistance to therapy. Better understanding of mechanisms that govern apoptosis has enabled identification of diverse routes by which melanomas manage to escape stimuli of apoptosis. Changes at genomic, transcriptional and post-translational levels of G-proteins and protein kinases (Ras, B-Raf) and their transcription factor effectors (c-Jun, ATF2, Stat3 and NF-kappaB) affects TNF, Fas and TRAIL receptors, which play important roles in acquiring melanoma's resistance to apoptosis. Here, we summarize our current understanding of changes that alters the regulation of death receptors during melanoma development.
引用
收藏
页码:3152 / 3161
页数:10
相关论文
共 125 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]   p53-Mdm2 - the affair that never ends [J].
Alarcon-Vargas, D ;
Ronai, Z .
CARCINOGENESIS, 2002, 23 (04) :541-547
[3]   Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles [J].
Andreola, G ;
Rivoltini, L ;
Castelli, C ;
Huber, V ;
Perego, P ;
Deho, P ;
Squarcina, P ;
Accornero, P ;
Lozupone, F ;
Lugini, L ;
Stringaro, A ;
Molinari, A ;
Arancia, G ;
Gentile, M ;
Parmiani, G ;
Fais, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) :1303-1316
[4]   Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy [J].
Aoki, K ;
Akyürek, LM ;
San, H ;
Leung, K ;
Parmacek, MS ;
Nabel, EG ;
Nabel, GJ .
MOLECULAR THERAPY, 2000, 1 (06) :555-565
[5]   Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo [J].
Aragane, Y ;
Maeda, A ;
Cui, CY ;
Tezuka, T ;
Kaneda, Y ;
Schwarz, T .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (06) :1008-1014
[6]   Gene transfer of Fas ligand induces tumor regression in vivo [J].
Arai, H ;
Gordon, D ;
Nabel, EG ;
Nabel, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (25) :13862-13867
[7]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[8]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[9]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[10]   Multiple roles of the tumor suppressor p53 [J].
Bargonetti, J ;
Manfredi, JJ .
CURRENT OPINION IN ONCOLOGY, 2002, 14 (01) :86-91